A comparison of the effects of HP 549 (Isoxepac), indomethacin and acetylsalicylic acid (Aspirin) on gastric mucosa in man.
To determine the reaction of the gastric mucosa to HP 549 (isoxepac) an oxo-dibenz-oxepine derivative of acetic acid and new non-steroidal antiphlogistic agent in comparison with standard drugs, 12 healthy volunteers received 3 g of Aspirin, 150 mg of indomethacin, or 600 mg of HP 549 (isoxepac) in a double-blind cross-over trial. Before and after each treatment period, all subjects underwent gastroscopy with biopsy of gastric mucosa. The subjects recorded complaints (side effects) before and after each treatment period. Aspirin produced significantly more gross mucosal changes at endoscopy. There was no significant difference between isoxepac and indomethacin. Both produced very few gastric mucosal changes and there were few subjective complaints.
D000085:Acetates / Q000009:adverse effects*; D000328:Adult; D001241:Aspirin / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003990:Dibenzoxepins / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects*; D005756:Gastritis / Q000139:chemically induced; D005773:Gastroscopy; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male
D000085:Acetates; D003990:Dibenzoxepins; C014904:isoxepac; D001241:Aspirin; D007213:Indomethacin